Rheumatoid Arthritis

Experimental drug PLX5622 has been shown in preclinical arthritis models to reduce inflammation, reduce cartilage damage, and prevent bone resorption.

With the advent of expensive laboratory tests and sophisticated imaging, the diagnosis of rheumatoid arthritis (RA) remains clinical. Because early detection is important for preventing clinical and radiographic progression, revision of the diagnostic criteria was needed and has been implemented.

Researchers plan to study the effects of hip replacement therapy on the employment and retirement decisions of older adults.

The American College of Rheumatology has put together a list of 13 myths about rheumatoid arthritis.

Arthritis patients benefit significantly when they receive homeopathy alongside conventional treatment over a period of six months.

Strong, positive marriages can help rheumatoid arthritis patients cope better.

Despite claims that biologics for treating rheumatoid arthritis are highly effective, Medicaid patients seem to demonstrate low adherence.

The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy.

European Union okays Vimovo for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis

A phase II clinical study began for Galapagos NV's drug candidate GLPG0259, a novel drug being developed for rheumatoid arthritis.

The standard DAS 28 score is the factor most strongly affecting the level of rheumatoid arthritis-related disability, according to a study in the Journal of Clinical Rheumatology.

Inflammatory arthritis includes a variety of diseases; the most common are rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. A large proportion of patients seen in most rheumatology practices have inflammatory arthritis; these patients also are seen in the primary care setting, where they present initially before a diagnosis has been made. The inflammatory arthritides are chronic progressive diseases that can cause irreversible joint damage even early in the disease course.

The main goal of this trial is to "evaluate the practical modalities and performance of the EULAR-RAID score in patients with rheumatoid arthritis who have been prescribed etanercept as part of usual medical practice."

Arthritis of the cricoarytenoid joints is not as rare as is commonly believed. Many sources still consider cricoarytenoid arthritis to be an atypical symptom of rheumatoid arthritis in spite of evidence to the contrary.

ABSTRACT: MRI allows for earlier detection of the joint synovitis, erosions, and bone marrow edema present in inflammatory arthritis, facilitating earlier diagnosis and treatment.

A new network from the University of Alabama at Birmingham (UAB) will create a national database that aims to see how rheumatoid arthritis (RA) patients respond to different RA drugs, and then use that information to further personalize RA treatment.

Dozens of posters were presented under the RA umbrella during the morning of day 4 at the American College of Rheumatology/Association of Rheumatology Health Professionals 2009 Annual Scientific Sessions.

RA patients identified through the Department of Veteran Affairs national administrative databases that were on anti-TNF therapy had a higher risk of developing non-melanoma skin cancer than those on non-biologic DMARDs.

Clinical study findings of recent years support the notion that patients with rheumatoid arthritis (RA) should be treated earlier and more aggressively. Monotherapy with disease-modifying antirheumatic drugs (DMARDs) is effective in some cases, but triple DMARD therapy is superior to double therapy or monotherapy in early or late RA. Leflunomide is at least as effective as methotrexate (MTX) and sulfasalazine and more effective than placebo.

Sustained disease-modifying antirheumatic drug (DMARD)-free remission occurs in about 10% of patients with rheumatoid arthritis (RA). It can be predicted by several clinical variables that are assessed routinely in outpatient clinics.

The impact of biomechanical factors on rheumatoid arthritis (RA) has gained increased attention from researchers, as evidenced by studies reported in Clinical Biomechanics. For example, reevaluating knee kinematics over time is important in patients with RA who wear a mobile-bearing total knee prosthesis, according to investigators at the Biomechanics and Imaging Group, Department of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.

Ultrasound may be a helpful tool for diagnosing and treating rheumatoid arthritis, a new study has found.

A prediction rule for the development of rheumatoid arthritis (RA) in patients with undifferentiated arthritis (UA) has been validated. The rule accurately estimates the risk of RA in more than 75% of patients with recent-onset UA.

Most patients with a confirmed diagnosis of rheumatoid arthritis (RA) use nonbiologic disease-modifying antirheumatic drugs (DMARDs), and the rate of biologic DMARD use is increasing rapidly, according to the American College of Rheumatology (ACR).The organization last updated recommendations for the use of nonbiologic DMARDs in 2002 and had not developed recommendations for using biologic agents.

Tumor necrosis factor α (TNF-α) inhibitor treatment for patients who have rheumatoid arthritis (RA) probably will reduce, not increase, the risk of heart failure if it effectively reduces inflammatory activity.